History

Highlights from our proud history:

2009/2010

APP Pharmaceuticals acts decisively to increase supply and alleviate critical market shortages following two voluntary recalls from other manufacturers of propofol injection. During this time, APP has become the sole supplier and increased production of Diprivan^® (propofol 1%), initiated and increased production of APP Propofol 1% (authorized generic Diprivan^®).  The company also supplemented supply by importing and distributing international Fresenius Propoven 1% (propofol 1%), in agreement with the FDA.

2009

APP Pharmaceuticals acquires its first southeast manufacturing facility in Raleigh, North Carolina.

2008

On September 10, 2008, APP Pharmaceuticals is acquired by Fresenius Kabi Pharmaceuticals Holding, Inc., making it an important part of a global leader in health care.

2008

APP works with FDA to dramatically increase manufacturing of heparin products after another manufacturer's recall. Becomes the sole supplier of heparin sodium vials in the U.S.

2007

APP becomes a stand-alone company known as APP Pharmaceuticals when it spins off from Abraxis BioScience.

2006

Abraxis BioScience is established. APP Division becomes Abraxis Pharmaceutical Products (APP). Acquired Puerto Rico facility.

2005

Abraxane™ is approved by the U.S. Food and Drug Administration and is launched.

2003

Named Cardinal Health Manufacturer of the Year, launched 12 new products; Abraxis Oncology is formed.

2001

Completed successful IPO, acquired U.S. marketing and exclusive manufacturing rights to Abraxane™, industry leading 12 ANDA approvals.

1998

Acquires Fujisawa's U.S. injectable business, including manufacturing capability and products.

1996

American Pharmaceutical Partners (APP) is established.